Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03604159 · ClinicalTrials.gov registry record · Phase 4
XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept
A Phase 4 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 52
- Enrollment target
NCT03604159 is a Phase 4 study that has completed, run by NYU Langone Health. The registered enrollment target is 52 participants.
The verdict
NCT03604159, a Phase 4 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 52 participants
- Enrollment target
Study Summary
This is a pilot proof-of-concept randomized controlled trial, open-label and unblinded, examining the feasibility and acceptability of Buprenorphine extended-release vs. daily sublingual buprenorphine-naloxone for the treatment of opioid use disorder in jail and at community re-entry.
Interventions
- DRUG Buprenorphine Extended Release
- DRUG Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2019-06-24 |
| Est. Completion | 2020-05-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03604159
The ClinicalTrials.gov registry entry for NCT03604159 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Buprenorphine Extended Release is the first listed.
NCT03604159 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03604159 about?
NCT03604159 is a clinical study titled "XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept". This is a pilot proof-of-concept randomized controlled trial, open-label and unblinded, examining the feasibility and acceptability of Buprenorphine extended-release vs. daily sublingual buprenorphine-naloxone for the treatment of opioid use disorder in jail and at community re-entry.
What is the current status of trial NCT03604159?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 52 participants. The study started on 2019-06-24. Estimated completion is 2020-05-04.
What interventions are being tested in trial NCT03604159?
The interventions under investigation include: Buprenorphine Extended Release (DRUG), Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets) (DRUG).
Who is sponsoring clinical trial NCT03604159?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.